Acorda Therapeutics, Inc. (CDG0.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
As of 09:23AM CEST. Market open.
| Previous Close | 0.4440 |
| Open | 0.4500 |
| Bid | 0.4500 x N/A |
| Ask | 0.4620 x N/A |
| Day's Range | 0.4500 - 0.4500 |
| 52 Week Range | 0.2840 - 4.0800 |
| Volume | |
| Avg. Volume | 51 |
| Market Cap | 11.158M |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.8130 |
| Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
- Business Wire
Acorda Therapeutics Reports Second Quarter 2022 Financial Results
PEARL RIVER, N.Y., August 04, 2022--Acorda Therapeutics Reports Second Quarter 2022 Financial Results
- Business Wire
Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022
ARDSLEY, N.Y., July 28, 2022--Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022
- Business Wire
Esteve Launches INBRIJA® in Germany
PEARL RIVER, N.Y., June 16, 2022--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor. (1)
© 2022 Yahoo. All rights reserved.
